L-asparaginase is a well-known antitumour metabolic therapy, employed in its pegylated form in the first-line treatment of childhood ALL since the early 2000s; by catalysing the deamination of L-asparagine, the enzyme depletes the asparagine and glutamine levels in lymphoblastic leukaemic cells, thus promoting their apoptotic death [188]. Here, ASPG is linked to acute lymphoblastic leukemia.